Pfizer hits 52-week high as turnaround takes hold
Alpha Vantage · The Motley Fool · · AI-summarised by FinFlash
Pfizer shares have climbed 20% year-to-date to a new 52-week high, signaling a possible turnaround from its post-pandemic slump. Cost-cutting, better-than-expected sales of non-COVID drugs and a promising pipeline are driving the gains, though key blockbuster patent expirations loom. The stock trades slightly above the $29.26 analyst target, leaving little near-term upside for investors.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.